Menu
Logo

DARZALEX® SC development

DARZALEX® SC was developed to reduce patient and provider burden without compromising safety and efficacy



Adapted with permission. © Halozyme, Inc. 2018. All rights reserved. © Janssen Pharmaceuticals, Inc.

Related content

DARZALEX® SC home

DARZALEX® SC handling and administration
Handling and administration demonstration & information

DARZALEX® SC studies
Overview of the DARZALEX® SC PAVO, COLUMBA and PLEIADES studies

DARZALEX® SC support materials
A range of materials, including a practical guide, in-clinic poster and patient materials

DARZALEX® SC MOA

DARZALEX® SC contains recombinant human hyaluronidase PH20 (rHuPH20; ENHANZE® drug delivery technology), an enzyme that disrupts the extracellular matrix to open the subcutaneous space, allowing access to the lymphatic and capillary vessels. The mechanism permits DARZALEX® SC to be absorbed quickly into the systemic circulation.[1][2][3]

DARZALEX® SC dose selection

The DARZALEX® SC 1,800 mg flat dose was selected based on the phase 1b PAVO study[4][5]

similar-clinical-response-rates
acceptable-pharmacokinetic-profile
comparable-safety-profile

DARZALEX® SC provides:[1]

shorter-administration
ready-to-use-vial
no-need-for-iv-access
greater-satisfaction

* Compared with DARZALEX® IV.

Quick downloads

SC Checklist beginning of treatment

Includes a first use checklist of Darzalex® SC.

Darzalex® SC Practical Guide

Includes DARZALEX® SC handling and administration info, pre and post-injection medications, and more

IRR: infusion-related reaction

IV: intravenous

MOA: mode of action

rHuPH20: recombinant human hyaluronidase PH20

SC: subcutaneous

Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.

Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.

Antes de prescrever consulte o RCM completo.

RCM de Darzalex®, veja aqui

CP-381997 - September 2023